DE188479T1 - Herstellung und reinigung von lymphokinen. - Google Patents
Herstellung und reinigung von lymphokinen.Info
- Publication number
- DE188479T1 DE188479T1 DE198585903275T DE85903275T DE188479T1 DE 188479 T1 DE188479 T1 DE 188479T1 DE 198585903275 T DE198585903275 T DE 198585903275T DE 85903275 T DE85903275 T DE 85903275T DE 188479 T1 DE188479 T1 DE 188479T1
- Authority
- DE
- Germany
- Prior art keywords
- csf
- protein
- thr
- leu
- giu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract 7
- 102000008072 Lymphokines Human genes 0.000 title 1
- 108010074338 Lymphokines Proteins 0.000 title 1
- 238000004140 cleaning Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract 26
- 102000004169 proteins and genes Human genes 0.000 claims abstract 25
- 239000002299 complementary DNA Substances 0.000 claims abstract 14
- 238000000034 method Methods 0.000 claims abstract 12
- 230000000694 effects Effects 0.000 claims abstract 10
- 239000013598 vector Substances 0.000 claims abstract 9
- 239000013612 plasmid Substances 0.000 claims abstract 5
- 230000009466 transformation Effects 0.000 claims abstract 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract 4
- 108020004999 messenger RNA Proteins 0.000 claims abstract 4
- 238000012258 culturing Methods 0.000 claims abstract 3
- 241000894006 Bacteria Species 0.000 claims abstract 2
- 239000006228 supernatant Substances 0.000 claims abstract 2
- 150000001413 amino acids Chemical group 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 201000010000 Agranulocytosis Diseases 0.000 claims 2
- 206010018687 Granulocytopenia Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 239000011324 bead Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 1
- ICRHGPYYXMWHIE-LPEHRKFASA-N Arg-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ICRHGPYYXMWHIE-LPEHRKFASA-N 0.000 claims 1
- SJUXYGVRSGTPMC-IMJSIDKUSA-N Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O SJUXYGVRSGTPMC-IMJSIDKUSA-N 0.000 claims 1
- YVXRYLVELQYAEQ-SRVKXCTJSA-N Asn-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N YVXRYLVELQYAEQ-SRVKXCTJSA-N 0.000 claims 1
- LTCKTLYKRMCFOC-KKUMJFAQSA-N Asp-Phe-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LTCKTLYKRMCFOC-KKUMJFAQSA-N 0.000 claims 1
- KSMSFCBQBQPFAD-GUBZILKMSA-N Cys-Pro-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 KSMSFCBQBQPFAD-GUBZILKMSA-N 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 claims 1
- IAJFFZORSWOZPQ-SRVKXCTJSA-N Leu-Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IAJFFZORSWOZPQ-SRVKXCTJSA-N 0.000 claims 1
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 claims 1
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 claims 1
- BTEMNFBEAAOGBR-BZSNNMDCSA-N Leu-Tyr-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BTEMNFBEAAOGBR-BZSNNMDCSA-N 0.000 claims 1
- 101150112468 OR51E2 gene Proteins 0.000 claims 1
- RIYZXJVARWJLKS-KKUMJFAQSA-N Phe-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RIYZXJVARWJLKS-KKUMJFAQSA-N 0.000 claims 1
- VTFXTWDFPTWNJY-RHYQMDGZSA-N Pro-Leu-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VTFXTWDFPTWNJY-RHYQMDGZSA-N 0.000 claims 1
- AWQGDZBKQTYNMN-IHRRRGAJSA-N Pro-Phe-Asp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)O)C(=O)O AWQGDZBKQTYNMN-IHRRRGAJSA-N 0.000 claims 1
- MDAWMJUZHBQTBO-XGEHTFHBSA-N Pro-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1)O MDAWMJUZHBQTBO-XGEHTFHBSA-N 0.000 claims 1
- UEKYKRQIAQHOOZ-KBPBESRZSA-N Pro-Trp Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)[O-])C(=O)[C@@H]1CCC[NH2+]1 UEKYKRQIAQHOOZ-KBPBESRZSA-N 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- WEQAYODCJHZSJZ-KKUMJFAQSA-N Ser-His-Tyr Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 WEQAYODCJHZSJZ-KKUMJFAQSA-N 0.000 claims 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 claims 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 claims 1
- VFEHSAJCWWHDBH-RHYQMDGZSA-N Thr-Arg-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VFEHSAJCWWHDBH-RHYQMDGZSA-N 0.000 claims 1
- IQHUITKNHOKGFC-MIMYLULJSA-N Thr-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IQHUITKNHOKGFC-MIMYLULJSA-N 0.000 claims 1
- NBIIPOKZPUGATB-BWBBJGPYSA-N Thr-Ser-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O NBIIPOKZPUGATB-BWBBJGPYSA-N 0.000 claims 1
- LYMVXFSTACVOLP-ZFWWWQNUSA-N Trp-Leu Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C([O-])=O)=CNC2=C1 LYMVXFSTACVOLP-ZFWWWQNUSA-N 0.000 claims 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000008366 buffered solution Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 108010034529 leucyl-lysine Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 108010080629 tryptophan-leucine Proteins 0.000 claims 1
- 108010051110 tyrosyl-lysine Proteins 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract 2
- 238000012216 screening Methods 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Fats And Perfumes (AREA)
- Debugging And Monitoring (AREA)
- Compounds Of Unknown Constitution (AREA)
- Detergent Compositions (AREA)
Claims (1)
- bei lage &igr;Anm. Nr. 85 9032 75.7 - PCT/EP 85/00326 EP Nr. 0 188 479 - WO 86/00639AnsprücheWir beanspruchen:
1. Rekombinantes CSF-Protein.2. CSF-Protein, das im Knochenmarktest eine spezifische Aktivität von IxIO7 Einheiten/mg aufweist.3. CSF-Protein, wie in Anspruch 2 beansprucht, welches rekombinantes CSF-Protein darstellt.4. CSF-Protein, wie in Anspruch 1 beansprucht, welches menschliches Granulozyten-Makrophagen-CSF darstellt.5. CSF-Protein, wie in Anspruch 1 beansprucht, welches die in Abb. 1 für CSF-thr, oder in Abb. 1 für CSF-ile, oder in Abb. für CSF-G gezeigte Aminosäuresequenz besitzt.6. Ein CSF-Protein, wie in Anspruch 1 beansprucht, das die wie in Abb. 1 gezeigte, mit Ala.Pro... beginnende Aminosäuresequenz besitzt oder worin der mit Ala.Pro... beginnenden Aminosäuresequenz ein Methioninrest vorhergeht.Anm. Nr. 85903275.7 - PCT/EP 85/00326 EP Nr. 0 188 479 - WO 86/006397. Ein CSF-Protein gemäss.Anspruch 1, das ein CSF-Protein darstellt, das in der Aminosäuresequenz einem in der Natur vorkommenden CSF entspricht, ausser dass eine oder mehrere Aminosäuren, ohne wesentliche Beeinflussung der biologischen Wirkung des natürlichen CSFs, zugefügt, ersetzt oder entfernt worden sind.8. Ein CSF-Protein gemäss Anspruch, das ein CSF-Proteindarstellt, welches die Aminosäuresequenz eines in der Natur vorkommenden CSFs besitzt, ausser dass ihm ein Methioninrest hervorgeht.9. Ein Verfahren zur Herstellung eines im Anspruch 1 beanspruchten CSF-Proteins, das beinhaltet, dass man das CSF-Protein so isoliert, wie es aus eukaryotisehen oder prokaryotisehen Wirtszellen exprimiert wird, in die ein Vektor transformiert wurde, wobei der Vektor einen für das CSF-Protein kodierenden Gen eingefügt enthält.lO.Ein Verfahren, wie in Anspruch 9 beansprucht, wobei die Expression aus E.coli, CHO oder Hefe erfolgt.11.Ein Verfahren zur Herstellung und Isolierung eines CSF/cDNA-enthaltenden Transformationsvektors, das beinhaltet:Herstellung von RNA aus einer CSF-produzierenden Zelle; Herstellung von polyadenylierter mRNA aus letzterer RNA; Herstellung von einzelsträngiger cDNA aus letzterer mRNA; Umwandlung der einzelsträngigen cDNA in doppelsträngige cDNA;0188Anm.Nr. 85903275.7 - PCT/EP 85/00326 EP Nr. 0 188 479 - WO 86/00639Einfügung der doppelsträngigen cDNA in Transformationsvektorenund Transformation von Bakterien mit dem genannten Vektor; Auslese von Pools von jeweils 200 bis 500 Kolonien undIsolierung von Plasmid-DNA aus jedem Pool; Transfektion der Plasmid-DNA in zur Expression von CSF-Protein geeignete Wirtszellen;Züchtung der transfizierten Zellen und Untersuchung des Ueberstehenden auf CSF-Aktivität; undAuswahl von CSF-positiven Pools und, zur Erkennung einerCSF-Aktivität besitzenden Kolonie, Sortieren der zum Aufbaudes Pools verwendeten Kolonien.12.Verfahren zur Reinigung von CSF-Protein aus einem Gemisch von in wässrigem Medium suspendierten Proteinen, das beinhaltet:Fällung des Proteins mit zu 80% gesättigtem Ammoniumsulfat zur Gewinnung eines das CSF-Protein enthaltenden Kügelchens;Resuspendierung des Kügelchens in eine gepufferte Lösung beibei einem pH-Wert im Bereich von etwa 6 bis etwa 8; Auflage der gepufferten, CSF-enthaltenden Lösung auf eine chromatographische Säule," Eluierung der CSF-Aktivität mit der gepufferten, Natriumchlorid-enthaltenden Lösung und Einsammeln der CSF-aktivität-besitzenden Fraktionen; undVereinigung der aktiven Fraktionen, Auflage der vereinigten Fraktionen auf eine C4 Phasenumkehrkolonne und Eluierung der CSF-Aktivität mit einem 0 bis 90%igen Acetonitrilgradienten zum Einsammeln der CSF-Aktivität enthaltenden Fraktionen.'13.CDNA, oder ein für CSF kodierender Expressionsvektor gemäss Anspruch 1.Anm.Nr. 85903275.7 - PCT/EP 85/00326 EP Nr. 0 188 479 - WO 86/0063914. Eine pharmazeutische Zubereitung enthaltend ein CSF gemäss Anspruch 1, bzw. CSF gemäss Anspruch 1 zur Verwendung in der Therapie.15. Ein Verfahren zur Behandlung von Infektion oder Granulozytopenie bzw. zur Aktivierung von Neutrophilen in Tieren, dadurch gekennzeichnet, dass man CSF gemäss Anspruch 1 einem diese Behandlung benötigenden Tier verabreicht, bzw. Verwendung von CSF gemäss Anspruch 1 zur Anwendung bei der Fabrikation von für ein solches Verfahren geeigneten pharmazeutischen Zubereitungen.16. Eine pharmazeutische Zubereitung enthaltend ein nach dem Verfahren gemäss Anspruch 12 hergestelltes CSF.17. Ein Verfahren zur Behandlung von Infektion oder Granulozytopenie bzw. zur Aktivierung von Neutrophilen in Tieren, dadurch gekennzeichnet, dass man CSF gemäss Anspruch 12 einem diese Behandlung benötigenden Tier verabreicht, bzw. Verwendung von CSF gemäss Anspruch 12 zur Anwendung bei der Fabrikation von für ein solches Verfahren geeigneten pharmazeutischen Zubereitungen.18. CSF-Protein, erhältlich über Expression des beim ATCC unter Nummer ATCC 39 754 hinterlegten E.coil MC 1061 oder der 127 Aminosäuren-, CSF-kodierenden Nukleotidsequenz vom dortin deponierten Plasmid &rgr; 91023(B)-CSF.3700/VA/DKGCT GGAGGATG TGGCTG CAG AGC CTG CTG CTC TTG GGC ACT GTG GCC TGC«ET Trp Leu GIn Ser Leu Leu Leu Leu GIy Thr VaI AIa CysI Ser CSF-G Arg CSF-G
&psgr; &Tgr; ■■■■■■ GAGC ATC TCT GCA CCC GCC CGC TCG CCC AGC CCC AGC ACG CAG CCC TGG GAG CATCSF-thr Ser IU Ser AIa Pro AIa Arg Ser Pro Ser Pro Ser Thr GIn Pro Trp GIu HisGTG AAT GCC ATC CAG GAG GCC CGG CGT CTC CTG AAC CTG AGT AGA GAC ACT GCT VaI Asn Ala lie Gin GIu Ala Arg Arg Leu Leu Asn Leu Ser Arg Asp Thr AIa200
Me CSF-G VaI CSF-GA GSCT GAG ATG AAT GAA ACA GTA GAA GTC ATC TCA GAA ATG TTT GAC CTC CAG GAG Ala GIu RET Asn GIu Thr VaI GIu VaI IU Ser GIu «ET Phe Asp Leu Gin GIu260G TCCG ACC TGC CTA CAG ACC CGC CTG GAG CTG TAC AAG CAG GGC CTG CAG GGC AGC Pro Thr Cys Leu GIn Thr Arg Leu GIu Leu Tyr Lys Gin GIy Leu Arg GIy SerCTC ACC AAG CTC AAG GGC CCC TTG ACC ATG ATG GCC AGC CAC TAC AAG CAG CAC Leu Thr Lys Leu Lys GIy Pro Leu Thr HET HET AIa Ser His Tyr Lys Gin HisIleCSF-ileAG TTGC CCT CCA ACC CCG GAA ACT TCC TGT GCA ACC CAG ACT ATC ACC TTT GAA AGT Cys Pro Pro Thr Pro GIu Thr Ser Cys AIa Thr GIn Thr IU Thr Phe GIu Ser380Thr CSF-G■'■ ■ ■ '■ ■, ■ ■ ■ . ■ ■■■ ■. .-. ' c ■■■■■TTC AAA GAG AAC CTG AAG GAC TTT CTG CTT GTC ATC CCC TTT GAC TGC TGG GAG Phe Lys GIu Asn Leu Lys Asp Phe Leu Leu VaI IU Pro Phe Asp Cys Trp GIu450 460 470 480 470 500
GIy CSF-GCCA GTC CAG GAG TGA GACCGGCCAG ATGAGGCTGG CCAAGCCGGG GAGCTGCTCT CTCATGAAACPro VaI Gin GIu .127510 520 530 540 550 560 570A G GAAGAGCTGGA AACTCAGGAT GGTCATCTTG CAGGGACCAA GGGGTGGGCC ACATCCATGG TGGGAGTGGC580 570 600 610 620 630 640CGGGACCTGC CCTGGGCCAC ACTGACCCTG ATACAGGCAT GGCAGAAGAA TGGGAATATT TTATACTGAC650 660 670 680 690 700 710AGAAATCAGT AATATTTATA TATTTATATT TTTAAAATAT TTATTTATTT ATTTATTTAA GTTCATATTC720 730 740 750 760 770 780CATATTTATT CAAGAT6TTT TACCGTAATA ATTATTATTA AAAATATGCT TCTAAAAAAA AAAAAAAAAA
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62834284A | 1984-07-06 | 1984-07-06 | |
US65274284A | 1984-09-19 | 1984-09-19 | |
US65244784A | 1984-09-19 | 1984-09-19 | |
PCT/EP1985/000326 WO1986000639A1 (en) | 1984-07-06 | 1985-07-04 | Lymphokine production and purification |
Publications (1)
Publication Number | Publication Date |
---|---|
DE188479T1 true DE188479T1 (de) | 1987-05-21 |
Family
ID=27417446
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE8585903275T Expired - Lifetime DE3584089D1 (de) | 1984-07-06 | 1985-07-04 | Herstellung und reinigung von lymphokinen. |
DE3588199T Expired - Lifetime DE3588199T2 (de) | 1984-07-06 | 1985-07-04 | Lymphokin-Herstellung und -Reinigung |
DE198585903275T Pending DE188479T1 (de) | 1984-07-06 | 1985-07-04 | Herstellung und reinigung von lymphokinen. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE8585903275T Expired - Lifetime DE3584089D1 (de) | 1984-07-06 | 1985-07-04 | Herstellung und reinigung von lymphokinen. |
DE3588199T Expired - Lifetime DE3588199T2 (de) | 1984-07-06 | 1985-07-04 | Lymphokin-Herstellung und -Reinigung |
Country Status (28)
Country | Link |
---|---|
EP (2) | EP0188479B1 (de) |
JP (4) | JP2540509B2 (de) |
KR (1) | KR910001809B1 (de) |
AT (2) | ATE67244T1 (de) |
AU (3) | AU599572B2 (de) |
CA (2) | CA1341618C (de) |
CY (1) | CY1629A (de) |
DE (3) | DE3584089D1 (de) |
DK (2) | DK168709B1 (de) |
ES (1) | ES8701226A1 (de) |
FI (1) | FI108796B (de) |
GR (1) | GR851643B (de) |
HK (2) | HK111594A (de) |
HU (1) | HU208711B (de) |
IE (2) | IE930961L (de) |
IL (2) | IL75725A (de) |
LU (1) | LU88337I2 (de) |
MY (1) | MY102902A (de) |
NL (1) | NL930089I2 (de) |
NO (4) | NO179455C (de) |
NZ (2) | NZ212645A (de) |
PL (1) | PL153139B1 (de) |
PT (1) | PT80776B (de) |
SA (1) | SA94150015A (de) |
SG (1) | SG108991G (de) |
SK (1) | SK280265B6 (de) |
UA (1) | UA39161C2 (de) |
WO (1) | WO1986000639A1 (de) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU594014B2 (en) * | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
JPS61227526A (ja) * | 1984-07-25 | 1986-10-09 | Chugai Pharmaceut Co Ltd | 新規なコロニー刺激因子 |
AU588819B2 (en) * | 1984-10-29 | 1989-09-28 | Immunex Corporation | Cloning of human granulocyte-macrophage colony stimulating factor gene |
ZA856108B (en) * | 1984-10-29 | 1986-10-29 | Immunex Corp | Cloning of human granulocyte-macrophage colony simulating factor gene |
IL77080A (en) * | 1984-11-20 | 1998-02-08 | Schering Biotech Corp | Polypeptides showing activity of human growth factor of macrophage granulocyte and eosinophils Vectors and cells transformed for their preparation and pharmaceutical preparations containing or |
EP0211899B1 (de) * | 1985-02-05 | 1992-09-23 | Cetus Oncology Corporation | Reinigung des natürlichen kolonie-stimulierenden faktors-1 |
ATE67517T1 (de) * | 1985-09-30 | 1991-10-15 | Chugai Pharmaceutical Co Ltd | Menschlicher granulozyten-colony stimulierender faktor. |
JPS63502795A (ja) * | 1985-10-03 | 1988-10-20 | バイオジェン インコーポレイテッド | 顆粒球‐マクロファージコロニー刺激因子‐様ポリペプチド、dna配列、組換えdna分子並びに微生物細胞中でヒト顆粒球−マクロファ−ジコロニ−刺激因子−様ポリペプチドを高収量で生産する方法 |
CA1295567C (en) * | 1988-07-25 | 1992-02-11 | Lawrence T. Malek | Expression system for the secretion of bioactive human granulocyte, macrophage-colony stimulating factor (gm-csf) and other heterologous proteins from streptomyces |
US5298603A (en) * | 1985-12-21 | 1994-03-29 | Hoechst Aktiengesellschaft | GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use |
DE3545568A1 (de) * | 1985-12-21 | 1987-07-16 | Hoechst Ag | Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung |
IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Factors that soak bone formation |
GR871029B (en) | 1986-07-14 | 1987-11-02 | Genetics Inst | Novel osteoinductive factors |
US5162111A (en) * | 1986-07-30 | 1992-11-10 | Grabstein Kenneth H | Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor |
WO1988001297A1 (en) * | 1986-08-11 | 1988-02-25 | Cetus Corporation | Expression of g-csf and muteins thereof |
GB8624899D0 (en) * | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
JPH0618781B2 (ja) * | 1986-10-18 | 1994-03-16 | 中外製薬株式会社 | 感染症治療剤 |
EP0276846A3 (de) * | 1987-01-29 | 1989-07-26 | Zymogenetics, Inc. | Derivate des koloniestimulierenden Faktors |
JP2521094B2 (ja) * | 1987-04-28 | 1996-07-31 | アムジェン、インコーポレーテッド | ヒト顆粒球マクロファ―ジコロニ―刺激因子をコ―ドする合成dna、そのdnaを含むプラスミド、およびそのdnaで形質転換された大腸菌 |
JPH03500481A (ja) * | 1987-06-25 | 1991-02-07 | イミュネックス・コーポレーション | ウシ顆粒球マクロファージコロニー刺激因子 |
KR930007430B1 (ko) * | 1987-07-16 | 1993-08-10 | 쉐링 코포레이션 | 크로마토그래피 단계에 의한 과립구-대식세포 콜로니-자극 인자의 정제방법 |
US5391706A (en) * | 1987-07-16 | 1995-02-21 | Schering Plough Corporation | Purification of GM-CSF |
IE63514B1 (en) * | 1987-07-17 | 1995-05-03 | Schering Biotech Corp | Expression vectors for the production of human granulocyte-macrophage colony stimulation factor in a mammalian cell host |
AU626530B2 (en) * | 1987-07-17 | 1992-08-06 | Schering Biotech Corporation | Human granulocyte-macrophage colony stimulating factor and muteins thereof |
CA1317244C (en) * | 1987-07-24 | 1993-05-04 | Ernest Seigo Kawasaki | Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system |
JPH03502582A (ja) * | 1988-05-31 | 1991-06-13 | シェリング・バイオテック・コーポレーション | 骨髄性白血病の治療方法 |
AU618283B2 (en) * | 1988-10-10 | 1991-12-19 | Instituto Nazionale Per Lo Studio E La Cura Dei Tumori | The use of GM-CSF in the treatment of a patient requiring high-dose chemo- or radiotherapy for cancer |
US5811523A (en) | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
JPH0322973A (ja) * | 1989-01-19 | 1991-01-31 | Wan Shen-Yuan | ヒトヘパトーム細胞系によるコロニー形成促進因子(CSFs)の構成性産生 |
EP0482086A1 (de) * | 1989-07-14 | 1992-04-29 | Schering Corporation | Vom carboxylende abgeleitete antagonisten von gm-csf |
CA2131190C (en) | 1992-02-28 | 2008-08-12 | Peter E. Lipsky | Compositions and methods for the treatment of thermal injury |
US6004807A (en) * | 1992-03-30 | 1999-12-21 | Schering Corporation | In vitro generation of human dendritic cells |
US6413509B1 (en) | 1992-11-24 | 2002-07-02 | S. Christopher Bauer | Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors |
US5738849A (en) * | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
US6361976B1 (en) | 1992-11-24 | 2002-03-26 | S. Christopher Bauer | Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production |
US5772992A (en) * | 1992-11-24 | 1998-06-30 | G.D. Searle & Co. | Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors |
US6361977B1 (en) | 1992-11-24 | 2002-03-26 | S. Christopher Bauer | Methods of using multivariant IL-3 hematopoiesis fusion protein |
US7091319B1 (en) | 1992-11-24 | 2006-08-15 | Bauer S Christopher | IL-3 variant hematopoiesis fusion protein |
US6057133A (en) * | 1992-11-24 | 2000-05-02 | G. D. Searle | Multivariant human IL-3 fusion proteins and their recombinant production |
US6403076B1 (en) | 1992-11-24 | 2002-06-11 | S. Christopher Bauer | Compositions for increasing hematopoiesis with interleukin-3 mutants |
US6153183A (en) * | 1992-11-24 | 2000-11-28 | G. D. Searle & Company | Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production |
EP1378572B1 (de) | 1993-05-12 | 2006-10-25 | Genetics Institute, LLC | BMP-11 Zusammenstellungen |
EP0646643B1 (de) * | 1993-06-30 | 2001-12-05 | Lucky Ltd. | Modifizierte-Granulocyte-Makrophage-Kolonie-stimulierender-Faktor-Gen und seine Expression in Hefe |
US6027919A (en) | 1993-12-07 | 2000-02-22 | Genetics Institute, Inc. | BMP-12 and BMP-13 proteins and DNA encoding them |
US5578301A (en) * | 1993-12-14 | 1996-11-26 | Sandoz Ltd. | Method for using GM-CSF to reduce the acute phase response in a patient being administered IL-6 therapy |
US5599536A (en) * | 1993-12-13 | 1997-02-04 | Sandoz Ltd. | Method for suppressing the acute phase response in a patient receiving IL-6 therapy |
US6165748A (en) | 1997-07-11 | 2000-12-26 | Genetics Institute, Inc. | Frazzled nucleotide sequences and expression products |
US6676937B1 (en) | 1998-03-09 | 2004-01-13 | Caritas St. Elizabeth's Medical Center Of Boston Inc. | Compositions and methods for modulating vascularization |
DE19905501B4 (de) | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels |
JP2002536404A (ja) * | 1999-02-12 | 2002-10-29 | ワシントン ユニバーシティー | 炎症性腸疾患を治療するための好中球機能の刺激 |
EP1276899A2 (de) * | 1999-12-10 | 2003-01-22 | Whitehead Institute For Biomedical Research | Ibd-verwandte polymorphismen |
US6869762B1 (en) | 1999-12-10 | 2005-03-22 | Whitehead Institute For Biomedical Research | Crohn's disease-related polymorphisms |
US6689599B1 (en) | 2000-10-20 | 2004-02-10 | Genetics Institute, Llc | Aggrecanase molecules |
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
AU2002319703A1 (en) | 2001-07-27 | 2003-02-17 | Wyeth | Aggrecanase molecules |
WO2003064622A2 (en) | 2002-01-31 | 2003-08-07 | Wyeth | Aggrecanase molecules |
KR20040088059A (ko) | 2002-02-05 | 2004-10-15 | 와이어쓰 | 절두된 아그레카나제 분자 |
CA2492444A1 (en) | 2002-07-29 | 2004-02-05 | Wyeth | Modified adamts4 molecules and method of use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4428632A (en) * | 1979-08-10 | 1984-01-31 | Thomas & Betts Corporation | Coaxial cable transition connector |
JPS6030654B2 (ja) * | 1980-12-31 | 1985-07-17 | 株式会社林原生物化学研究所 | ヒトコロニ−刺激因子の製造方法 |
US4438032A (en) * | 1981-01-30 | 1984-03-20 | The Regents Of The University Of California | Unique T-lymphocyte line and products derived therefrom |
JPH0751511B2 (ja) * | 1982-03-15 | 1995-06-05 | 味の素株式会社 | インターロイキン2を含有してなる癌治療剤 |
AU594014B2 (en) * | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
ZA856108B (en) * | 1984-10-29 | 1986-10-29 | Immunex Corp | Cloning of human granulocyte-macrophage colony simulating factor gene |
AU588819B2 (en) * | 1984-10-29 | 1989-09-28 | Immunex Corporation | Cloning of human granulocyte-macrophage colony stimulating factor gene |
-
1985
- 1985-07-04 WO PCT/EP1985/000326 patent/WO1986000639A1/en active IP Right Grant
- 1985-07-04 EP EP85903275A patent/EP0188479B1/de not_active Expired - Lifetime
- 1985-07-04 ES ES544868A patent/ES8701226A1/es not_active Expired
- 1985-07-04 GR GR851643A patent/GR851643B/el unknown
- 1985-07-04 KR KR1019860700138A patent/KR910001809B1/ko not_active IP Right Cessation
- 1985-07-04 IE IE930961A patent/IE930961L/xx not_active IP Right Cessation
- 1985-07-04 DE DE8585903275T patent/DE3584089D1/de not_active Expired - Lifetime
- 1985-07-04 NZ NZ212645A patent/NZ212645A/xx unknown
- 1985-07-04 AU AU45456/85A patent/AU599572B2/en not_active Expired
- 1985-07-04 UA UA4027096A patent/UA39161C2/uk unknown
- 1985-07-04 IL IL75725A patent/IL75725A/xx not_active IP Right Cessation
- 1985-07-04 AT AT85903275T patent/ATE67244T1/de active
- 1985-07-04 HU HU853131A patent/HU208711B/hu unknown
- 1985-07-04 DE DE3588199T patent/DE3588199T2/de not_active Expired - Lifetime
- 1985-07-04 JP JP60503011A patent/JP2540509B2/ja not_active Expired - Lifetime
- 1985-07-04 IE IE169585A patent/IE60819B1/en not_active IP Right Cessation
- 1985-07-04 DE DE198585903275T patent/DE188479T1/de active Pending
- 1985-07-04 NZ NZ228031A patent/NZ228031A/en unknown
- 1985-07-04 EP EP89106339A patent/EP0337359B1/de not_active Expired - Lifetime
- 1985-07-04 AT AT89106339T patent/ATE172494T1/de not_active IP Right Cessation
- 1985-07-05 PT PT80776A patent/PT80776B/pt unknown
- 1985-07-05 PL PL1985254400A patent/PL153139B1/pl unknown
- 1985-07-05 CA CA486372A patent/CA1341618C/en active Active
- 1985-07-05 SK SK5059-85A patent/SK280265B6/sk unknown
-
1986
- 1986-01-22 FI FI860308A patent/FI108796B/fi not_active IP Right Cessation
- 1986-03-03 NO NO860775A patent/NO179455C/no not_active IP Right Cessation
- 1986-03-06 DK DK102886A patent/DK168709B1/da not_active IP Right Cessation
-
1987
- 1987-09-22 MY MYPI87001870A patent/MY102902A/en unknown
-
1989
- 1989-08-21 AU AU40090/89A patent/AU628069B2/en not_active Expired
-
1990
- 1990-05-14 AU AU54976/90A patent/AU644359B2/en not_active Expired
- 1990-06-17 IL IL94754A patent/IL94754A0/xx not_active IP Right Cessation
-
1991
- 1991-12-24 SG SG1089/91A patent/SG108991G/en unknown
-
1992
- 1992-07-10 CY CY1629A patent/CY1629A/xx unknown
-
1993
- 1993-05-21 DK DK199300594A patent/DK172679B1/da not_active IP Right Cessation
- 1993-06-22 JP JP5176039A patent/JP2594744B2/ja not_active Expired - Lifetime
- 1993-06-22 JP JP5175978A patent/JP2594743B2/ja not_active Expired - Lifetime
- 1993-06-24 NL NL930089C patent/NL930089I2/nl unknown
- 1993-06-25 LU LU88337C patent/LU88337I2/fr unknown
-
1994
- 1994-06-20 SA SA94150015A patent/SA94150015A/ar unknown
- 1994-09-07 NO NO19943300A patent/NO314941B1/no not_active IP Right Cessation
- 1994-10-12 HK HK111594A patent/HK111594A/xx not_active IP Right Cessation
- 1994-10-19 JP JP6253317A patent/JP2594768B2/ja not_active Expired - Lifetime
-
1996
- 1996-01-05 CA CA000617042A patent/CA1340852C/en not_active Expired - Lifetime
- 1996-04-12 NO NO961452A patent/NO307348B1/no not_active IP Right Cessation
- 1996-12-18 NO NO1996016C patent/NO1996016I1/no unknown
-
1998
- 1998-12-04 HK HK98112849A patent/HK1011709A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE188479T1 (de) | Herstellung und reinigung von lymphokinen. | |
DE69733204T3 (de) | Neuartige vegf-ähnliche faktoren | |
DE68908491T2 (de) | Insulinvorläufer, deren Herstellung und DNA-Sequenzen, Expressionsvehikel und Primer und ein Prozess zur Herstellung von Humaninsulin und Analoge. | |
DE3486216T2 (de) | Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren. | |
DE3786767T3 (de) | Neues Polypeptid. | |
DE69433648T2 (de) | Menschliche chemokin-polypeptide | |
DE3382575T2 (de) | Dna-sequenzen, rekombinante dna-molekuele und verfahren zur herstellung von schweinewachstumshormonaehnlichen polypeptiden. | |
DD212982A5 (de) | Verfahren zur herstellung von rinder-wachstumshormon-aehnlichen polypeptiden | |
DE69117123T2 (de) | Menschliches MK Gen und Protein-Sequenz | |
DE19532001A1 (de) | Neues Peptid, Antibakterielles Agens, neues Peptidgen, neue Rekombinante DNA und Verfahren zur Herstellung des neuen Peptids | |
DE19535853A1 (de) | Varianten des humanen rekombinanten Interferon-gamma (rhu-IFN-gamma) mit erhöhter thermischer Stabilität | |
EP0736095B1 (de) | Humanes zirkulierendes cytokin cc-1 | |
WO1990007579A1 (de) | Tumor nekrose faktor muteine | |
DE69131421T3 (de) | Für den rezeptor des granulozytenkolonie stimulierenden faktors kodierende dns | |
DE69434997T2 (de) | Menschliches Chondromodulin-I-Protein | |
EP1287142B1 (de) | Nukleinsaure-molekul umfassend eine fur ein sdf-1 gamma chemokin,einen neuropeptid-prakursor oder mindestens ein neuropeptid kodierende nukleinsauresequenz | |
DE3882611T2 (de) | Menschliches Interleukin-4, Expressionsvektoren dafür und diese enthaltende Transformanten. | |
DE3881123T2 (de) | Klonieren von für einen antibakteriellen Polypeptidvorläufer kodierender DNA und Expression des Vorläufers. | |
DE69836853T2 (de) | Etablierte Mikrogliazellen | |
DE69434090T2 (de) | Epsilon-untereinheit des gaba a-rezeptors | |
DE3688816T2 (de) | Dns-sequenz. | |
WO1997020049A1 (de) | Humanes, im blut zirkulierendes peptid mit insulinotroper wirkung | |
DE602004002400T2 (de) | Peptide, die fähig sind, die Aktivität der Engrailed-Transkriptionsfaktoren zu modifizieren | |
AT398433B (de) | Transforming growth faktor beta1/transforming growth faktor beta2-hybrid-prekursor und dafür codierende nucleotidsequenz | |
WO1998045428A1 (de) | Fanconi-gen ii |